Mass. Man Details Sudden Blindness from GLP-1 Ozempic

In this interview with Boston 25 News [00:00], Massachusetts resident Ed shares his harrowing experience of losing his sight completely within days [01:54]. A state highway worker prescribed Ozempic to manage his A1C levels [16:34], Ed woke up in May 2025 with vision issues that rapidly deteriorated to full blindness [00:06]. A neuro-ophthalmologist linked his sudden vision loss to the GLP-1 drug, noting symptoms of NAION (non-arteritic anterior ischemic optic neuropathy) [02:45, 03:05].

The life-altering side effect forced Ed to stop working [05:30] and adjust to a new reality. After attending a 14-week training program at the Carroll Center for the Blind [06:39], he is learning to navigate daily tasks, finances, and independence without sight [07:05, 08:10]. Ed has joined a lawsuit against the drug manufacturer to seek financial recovery and raise awareness [04:14, 12:13, 14:48]. He hopes to become an advocate and support group leader for others facing sudden, devastating vision loss [12:13, 13:34].

The medical condition described in Ed’s case is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), often dubbed “eye stroke.” NAION occurs when blood flow to the optic nerve is suddenly reduced, causing rapid, painless, and typically permanent vision loss—frequently noticed upon waking.

Despite making headline news, NAION remains an extremely rare side effect. In the general population over 50, NAION occurs in roughly 2 to 10 out of 100,000 people annually. However, observational research—such as a landmark Harvard study published in JAMA Ophthalmology—revealed a heightened correlation among GLP-1 users. The study found that patients taking semaglutide (Ozempic/Wegovy) for type 2 diabetes faced a four-fold risk, while those using it for weight loss faced up to a seven-fold risk compared to non-users.

In absolute terms, the risk is still very low: roughly 0.4% to 0.7% over three years, or fewer than 1 in 1,000 patients. Organizations like the American Academy of Ophthalmology note that while a correlation exists, direct causation is not definitively proven. Because no effective treatment currently exists for NAION, regulatory agencies and medical experts advise patients to monitor sudden vision changes while maintaining open communication with their doctors.